Conditions: Relapsing Remitting Multiple Sclerosis
Keywords: Multiple sclerosis Fingolimod Disease Modifying Therapy TSQM-9
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 61
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care, using the global satisfaction subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM-9).

Detailed description:

Arms:
arm 1: Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period. arm 2: Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.

Interventions: intervention 1: Fingolimod intervention 2: Standard MS DMT
Intervention descriptions: intervention 1: 0.5 mg/day oral capsule intervention 2: Interferon beta 1a or interferon beta 1b or Glatiramer Acetate

Protocol document: